Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-TTRSC04 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-TTRSC04 | EXPERIMENTAL | Participants will be administered a single dose of ALN-TTRSC04. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of placebo. |
| Name | Type | Description |
|---|---|---|
| ALN-TTRSC04 | DRUG | ALN-TTRSC04 will be administered by subcutaneous (SC) injection. |
| Placebo | DRUG | Placebo will be administered by SC injection. |
Inclusion Criteria: * Body mass index (BMI) ≥18.0 kg/m\^2 and ≤30 kg/m\^2 assessed at Screening. Exclusion Criteria: * Has an estimated glomerular filtration rate (eGFR) \<90 mL/min/1.73m\^2 at screening. * Has alanine aminotransferase (ALT), aspartate aminotransferase (AST) or direct bilirubin a...
ALN-TTRSC is an investigational drug being developed for transthyretin-mediated amyloidosis (ATTR amyloidosis), a rare disease. It is currently in Phase 1 clinical development. The drug is being studied in healthy volunteers to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics.
ALN-TTRSC is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company. The company's stock ticker is ALNY. The drug is currently in Phase 1 clinical trials for transthyretin-mediated amyloidosis.
ALN-TTRSC is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to assess its safety and tolerability.
ALN-TTRSC has been studied in three completed Phase 1 clinical trials. These include NCT01814839, NCT02797847, and NCT05661916. All trials were conducted in the United Kingdom and enrolled healthy volunteers aged 18 years and older.
ALN-TTRSC is also known as revusiran. In clinical trial NCT01814839, the drug is referred to as ALN-TTRSC (Revusiran). The drug is being developed for transthyretin-mediated amyloidosis.